Literature DB >> 35249120

External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection.

Vito Lorusso1,2,3, Boukary Kabre4, Geraldine Pignot5, Nicolas Branger5, Andrea Pacchetti5, Jeanne Thomassin-Piana6, Serge Brunelle7, Nicola Nicolai8, Gennaro Musi9,10, Naji Salem11, Emanuele Montanari9,12, Ottavio de Cobelli9,10, Gwenaelle Gravis13, Jochen Walz5.   

Abstract

PURPOSE: Prostate cancer (PCa) imaging has been revolutionized by the introduction of multi-parametric Magnetic Resonance Imaging (mpMRI). Transrectal ultrasound (TRUS) has always been considered a low-performance modality. To overcome this, a computerized artificial neural network analysis (ANNA/C-TRUS) of the TRUS based on an artificial intelligence (AI) analysis has been proposed. Our aim was to evaluate the diagnostic performance of the ANNA/C-TRUS system and its ability to improve conventional TRUS in PCa diagnosis.
METHODS: We retrospectively analyzed data from 64 patients with PCa and scheduled for radical prostatectomy who underwent TRUS followed by ANNA/C-TRUS analysis before the procedure. The results of ANNA/C-TRUS analysis with whole mount sections from final pathology.
RESULTS: On a per-sectors analysis, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and accuracy were 62%, 81%, 80%, 64% and 78% respectively. The values for the detection of clinically significant prostate cancer were 69%, 77%, 88%, 50% and 75%. The diagnostic values for high grade tumours were 70%, 74%, 91%, 41% and 74%, respectively. Cancer volume (≤ 0.5 or greater) did not influence the diagnostic performance of the ANNA/C-TRUS system.
CONCLUSIONS: ANNA/C-TRUS represents a promising diagnostic tool and application of AI for PCa diagnosis. It improves the ability of conventional TRUS to diagnose prostate cancer, preserving its simplicity and availability. Since it is an AI system, it does not hold the inter-observer variability nor a learning curve. Multicenter biopsy-based studies with the inclusion of an adequate number of patients are needed to confirm these results.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  ANNA; Artificial intelligence; Biopsy; C-TRUS; Diagnosis; Imaging; Prostate cancer; TRUS; Transrectal; Ultrasound

Year:  2022        PMID: 35249120     DOI: 10.1007/s00345-022-03965-w

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

1.  The ultrasonic field as a medical tool.

Authors:  K T DUSSIK
Journal:  Am J Phys Med       Date:  1954-02

Review 2.  Artificial neural networks and prostate cancer--tools for diagnosis and management.

Authors:  Xinhai Hu; Henning Cammann; Hellmuth-A Meyer; Kurt Miller; Klaus Jung; Carsten Stephan
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

3.  Medical imaging by NMR.

Authors:  P Mansfield; A A Maudsley
Journal:  Br J Radiol       Date:  1977-03       Impact factor: 3.039

4.  [Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma].

Authors:  T Loch; I Leuschner; C Genberg; K Weichert-Jacobsen; F Küppers; M Retz; J Lehmann; E Yfantis; M Evans; V Tsarev; M Stöckle
Journal:  Urologe A       Date:  2000-07       Impact factor: 0.639

5.  Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound.

Authors:  T Loch; I Leuschner; C Genberg; K Weichert-Jacobsen; F Küppers; E Yfantis; M Evans; V Tsarev; M Stöckle
Journal:  Prostate       Date:  1999-05-15       Impact factor: 4.104

6.  Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

Authors:  P M Beemsterboer; R Kranse; H J de Koning; J D Habbema; F H Schröder
Journal:  Int J Cancer       Date:  1999-08-20       Impact factor: 7.396

7.  Advanced ultrasound in the diagnosis of prostate cancer.

Authors:  Jean-Michel Correas; Ethan J Halpern; Richard G Barr; Sangeet Ghai; Jochen Walz; Sylvain Bodard; Charles Dariane; Jean de la Rosette
Journal:  World J Urol       Date:  2020-04-18       Impact factor: 4.226

Review 8.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Roderick C N van den Bergh; Erik Briers; Thomas Van den Broeck; Marcus G Cumberbatch; Maria De Santis; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikos Grivas; Jeremy Grummet; Ann M Henry; Theodorus H van der Kwast; Thomas B Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Lisa Moris; Daniela E Oprea-Lager; Henk G van der Poel; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Thomas Wiegel; Peter-Paul M Willemse; Philip Cornford
Journal:  Eur Urol       Date:  2020-11-07       Impact factor: 20.096

9.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.